Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirexatamab + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Leap Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sirexatamab + pembrolizumab is an investigational combination therapy being developed by Leap Therapeutics for the treatment of advanced or recurrent endometrial cancer. Sirexatamab (DKN-01) is a humanized monoclonal antibody that targets Dickkopf-related protein 1 (DKK1), a secreted protein that modulates the Wnt signaling pathway and is associated with tumor growth and immune suppression. Pembrolizumab is a well-established anti-PD-1 checkpoint inhibitor. The combination aims to synergistically enhance anti-tumor immune responses by simultaneously inhibiting DKK1-mediated immune evasion and restoring T-cell activity through PD-1 blockade. This regimen is currently being evaluated in a Phase 2 clinical trial (NCT05761951) specifically in patients with DKK1-high endometrial tumors.
- Other names
- DKN-01 + pembrolizumab
02
Targets
DKK1 (Dickkopf-related protein 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sirexatamab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirexatamab + pembrolizumab.